HUTCHMED (China) Ltd
HCM
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,811
Stocks News & Analysis
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
stocks
What AI means for US software companies’ moats
We’re no longer certain that software firms will outperform over the next decade, but positive outcomes remain possible for names like Salesforce.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.60 | 16.90 | -0.19% |
| CAC 40 | 7,915.36 | 78.13 | -0.98% |
| DAX 40 | 23,394.38 | 196.65 | -0.83% |
| Dow JONES (US) | 47,706.01 | 204.46 | 0.43% |
| FTSE 100 | 10,249.52 | 35.23 | -0.34% |
| HKSE | 25,408.46 | 348.83 | -1.35% |
| NASDAQ | 22,677.31 | 289.63 | 1.29% |
| Nikkei 225 | 52,728.72 | 2,892.12 | -5.20% |
| NZX 50 Index | 13,098.83 | 519.06 | -3.81% |
| S&P 500 | 6,790.58 | 50.56 | 0.75% |
| S&P/ASX 200 | 8,599.00 | 3.30 | -0.04% |
| SSE Composite Index | 4,096.60 | 27.59 | -0.67% |